Uncovering the clinicopathological features of early recurrence after surgical resection of pancreatic cancer

Hye Yeon Chon,Hee Seung Lee,You-Na Sung,Yoo Keung Tae,Chan Hee Park,Galam Leem,So Jung Kim,Jung Hyun Jo,Moon Jae Chung,Jeong Youp Park,Seung Woo Park,Seung-Mo Hong,Seungmin Bang

DOI: https://doi.org/10.1038/s41598-024-52909-4

IF: 4.6

2024-02-06

Scientific Reports

Abstract:To identify risk factors and biomarker for early recurrence in patients diagnosed with pancreatic cancer who undergo curative resection. Early recurrence after curative resection of pancreatic cancer is an obstacle to long-term survival. We retrospectively reviewed 162 patients diagnosed with pancreatic cancer who underwent curative resection. Early recurrence was defined as recurrence within 12 months of surgery. We selected S100A2 as a biomarker and investigated its expression using immunohistochemistry. Of the total, 79.6% (n = 129) of patients received adjuvant chemotherapy after surgery and 117 (72.2%) experienced recurrence, of which 73 (45.1%) experience early recurrence. In multivariate analysis, age < 60 years, presence of lymph node metastasis, and no adjuvant chemotherapy were significantly associated with early recurrence (all P 5) was significantly lower in the early recurrence group (41.5% vs . 63.3%, P = 0.020). The cumulative incidence rate of early recurrence was higher in patients with an S100A2 H-score < 5 (41.5% vs. 63.3%, P = 0.012). The median overall survival of patients with higher S100A2 expression was longer than those with lower S100A2 expression (median 30.1 months vs . 24.2 months, P = 0.003). High-risk factors for early recurrence after surgery for pancreatic cancer include young age, lymph node metastasis, and no adjuvant therapy. Neoadjuvant treatment or intensive adjuvant therapy after surgery may improve the prognosis of patients with high-risk signatures. In patients who receive adjuvant therapy, high S100A2 expression is a good predictor.

multidisciplinary sciences

What problem does this paper attempt to address?

This paper aims to address the risk factors and biomarkers of early recurrence after pancreatic cancer surgery. Pancreatic cancer is a disease with extremely poor prognosis, and its 5 - year survival rate is less than 5%. Although surgical resection is one of the main methods for treating pancreatic cancer, the postoperative recurrence rate is very high, especially early recurrence (defined as recurrence within 12 months after surgery), which seriously affects the long - term survival of patients. Therefore, identifying patients at high risk of early recurrence is of great significance for improving prognosis.

### Research Background and Objectives

1. **Research Background**:
- Pancreatic cancer is a highly lethal cancer with a 5 - year survival rate of less than 5%. It is the seventh leading cause of cancer death worldwide and is expected to become the second leading cause of cancer - related death by 2030.
- Late - stage diagnosis and unresectable pancreatic cancer are major problems, but even in the resectable cases, the postoperative recurrence rate is also very high, especially early recurrence.
- Early recurrence has raised doubts about the effectiveness of surgical treatment for pancreatic cancer, so it is necessary to identify patients at high risk of early recurrence.

2. **Research Objectives**:
- Identify the risk factors and biomarkers of early recurrence after pancreatic cancer surgery.
- Explore the relationship between S100A2 protein expression and early recurrence, as well as its potential as a predictive indicator.

### Main Findings

1. **Risk Factors**:
- **Age**: Patients younger than 60 years are more likely to have early recurrence.
- **Lymph Node Metastasis**: The risk of early recurrence in patients with lymph node metastasis is significantly increased.
- **Adjuvant Chemotherapy**: Patients who have not received adjuvant chemotherapy have a higher risk of early recurrence.

2. **Biomarkers**:
- **S100A2 Protein**: Patients with a higher level of S100A2 protein expression (H - score > 5) have a lower risk of early recurrence and a longer overall survival time.
- The level of S100A2 protein expression is related to the effect of adjuvant chemotherapy, and patients with high expression benefit more from adjuvant chemotherapy.

### Conclusion

This study retrospectively analyzed the clinical data of 162 patients with pancreatic cancer who underwent surgical resection and found the relationships between factors such as age, lymph node metastasis, and adjuvant chemotherapy and early recurrence. In addition, the S100A2 protein expression level was identified as a potential biomarker that can predict the risk of early recurrence. These findings are helpful for better identifying high - risk patients, thereby formulating more effective treatment strategies, such as neoadjuvant treatment or intensified adjuvant treatment, to improve the prognosis of patients.